Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315223000346/form10-k.htm
December 2022
September 2022
August 2022
April 2022
March 2022
December 2021
October 2021
October 2021
June 2021
May 2021
Cover - USD ($) | 12 Months Ended | ||
---|---|---|---|
Oct. 31, 2022 | Jan. 05, 2023 | Apr. 29, 2022 | |
Cover [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Annual Report | true | ||
Document Transition Report | false | ||
Document Period End Date | Oct. 31, 2022 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2022 | ||
Current Fiscal Year End Date | --10-31 | ||
Entity File Number | 001-37492 | ||
Entity Registrant Name | ANIXABIOSCIENCES, INC. | ||
Entity Central Index Key | 0000715446 | ||
Entity Tax Identification Number | 11-2622630 | ||
Entity Incorporation, State or Country Code | DE | ||
Entity Address, Address Line One | 3150Almaden Expressway | ||
Entity Address, Address Line Two | Suite 250 | ||
Entity Address, City or Town | SanJose | ||
Entity Address, State or Province | CA | ||
Entity Address, Postal Zip Code | 95118 | ||
City Area Code | (408) | ||
Local Phone Number | 708-9808 | ||
Title of 12(b) Security | Common Stock, $0.01 par value | ||
Trading Symbol | ANIX | ||
Security Exchange Name | NASDAQ | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Voluntary Filers | No | ||
Entity Current Reporting Status | Yes | ||
Entity Interactive Data Current | Yes | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | false | ||
Entity Shell Company | false | ||
Entity Public Float | $ 93,235,194 | ||
Entity Common Stock, Shares Outstanding | 30,920,792 | ||
Documents Incorporated by Reference [Text Block] | NONE | ||
ICFR Auditor Attestation Flag | false | ||
Auditor Firm ID | 200 | ||
Auditor Name | HASKELL& WHITE LLP | ||
Auditor Location | Irvine,California |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/715446/000149315223000346/form10-k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Anixa Biosciences Inc.
Anixa Biosciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:
Rating
Learn More![]()
The net loss attributable to noncontrolling interest, representing Wistar's 5% ownership interest in Certainty's net loss, increased by approximately $2,000 to approximately $176,000 in fiscal year 2022, from approximately $174,000 in fiscal year 2021, as Certainty's net loss increased.
Accordingly, the performance obligations from the license were satisfied and 100% of the revenue was recognized upon execution of the license agreement.
Accordingly, the performance obligations from these agreements were satisfied and 100% of the revenue was recognized upon the execution of the agreements.
Cash provided by financing activities was approximately $452,000, resulting proceeds from exercise of stock options of approximately $439,000 and proceeds from the sale of common stock pursuant to employee stock purchase plan of approximately $13,000.
We can give no assurance that we will generate sufficient cash flows in the future to satisfy our liquidity requirements or sustain future operations, or that other sources of funding, such as sales of equity or debt, would be available or would be approved by our security holders, if needed, on favorable terms or at all.
General and administrative expenses increased...Read more
The increase in research and...Read more
As a result, our cash,...Read more
Our revenue arrangements provide for...Read more
Cash used in investing activities...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Anixa Biosciences Inc provided additional information to their SEC Filing as exhibits
Ticker: ANIX
CIK: 715446
Form Type: 10-K Annual Report
Accession Number: 0001493152-23-000346
Submitted to the SEC: Wed Jan 04 2023 4:59:57 PM EST
Accepted by the SEC: Wed Jan 04 2023
Period: Monday, October 31, 2022
Industry: Medical Laboratories